B. Klein, X. Zhang, and M. Jourdan, Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6, Blood, vol.73, pp.517-543, 1989.

M. Kawano, T. Hirano, and T. Matsuda, Autocrine generation and essential requirement of BSF-2/IL- 6 for human multiple myeloma, pp.83-88, 1988.

B. Klein, K. Tarte, and M. Jourdan, Survival and Proliferation Factors of Normal and Malignant Plasma Cells, International Journal of Hematology, vol.276, issue.2, pp.106-119, 2003.
DOI : 10.1007/BF02983377
URL : https://hal.archives-ouvertes.fr/inserm-00130900

M. Ferlin, N. Noraz, and C. Hertogh, Insulin-like growth factor induces the survival and proliferation of myeloma cells through an IL-6-independent transduction pathway, British Journal of Haematology, vol.111, pp.626-660, 2000.

P. Georgii-hemming, H. Wiklund, O. Ljunggren, and N. , Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines, Blood, vol.88, pp.2250-2258, 1996.

M. Ferlin-bezombes, J. M. Liautard, and J. , IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis, J.Immunol, vol.161, pp.2692-2701, 1998.

Z. Lu, X. Zhang, and C. Rodriguez, Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells, Blood, vol.85, pp.2521-2528, 1995.

P. Derksen, R. Keehnen, and L. Evers, Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma, Blood, vol.99, issue.4, pp.1405-1415, 2002.
DOI : 10.1182/blood.V99.4.1405

P. Derksen, E. Tjin, and H. Meijer, Illegitimate WNT signaling promotes proliferation of multiple myeloma cells, Proceedings of the National Academy of Sciences, vol.101, issue.16, pp.6122-6129, 2004.
DOI : 10.1073/pnas.0305855101

K. Mahtouk, F. Cremer, and T. Reme, Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma, Oncogene, vol.83, issue.54, pp.7180-91, 2006.
DOI : 10.1038/sj.onc.1209699
URL : https://hal.archives-ouvertes.fr/inserm-00128880

J. Moreaux, E. Legouffe, and E. Jourdan, BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone, Blood, vol.103, issue.8, pp.3148-57, 2004.
DOI : 10.1182/blood-2003-06-1984
URL : https://hal.archives-ouvertes.fr/inserm-00129502

M. Attal, J. Harousseau, and T. Facon, Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma, New England Journal of Medicine, vol.349, issue.26, pp.2495-502, 2003.
DOI : 10.1056/NEJMoa032290

B. Bruno, M. Rotta, and F. Patriarca, A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma, New England Journal of Medicine, vol.356, issue.11, pp.1110-1130, 2007.
DOI : 10.1056/NEJMoa065464

F. Piazza, C. Gurrieri, L. Trentin, and S. , Towards a new age in the treatment of multiple myeloma, Annals of Hematology, vol.10, issue.22, pp.159-72, 2007.
DOI : 10.1007/s00277-006-0239-5

M. Higgins, R. Fonseca, and . Genetics-of-multiple-myeloma, Genetics of multiple myeloma, Best Practice & Research Clinical Haematology, vol.18, issue.4, pp.525-561, 2005.
DOI : 10.1016/j.beha.2005.01.006

M. Gertz, M. Lacy, and A. Dispenzieri, Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy, Blood, vol.106, issue.8, pp.2837-2877, 2005.
DOI : 10.1182/blood-2005-04-1411

N. Kroger, G. Schilling, and H. Einsele, Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation, Blood, vol.103, issue.11, pp.4056-61, 2004.
DOI : 10.1182/blood-2003-12-4435

H. Avet-loiseau, M. Attal, and P. Moreau, Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation, Blood, vol.19108, pp.1724-1756, 2006.

F. Magrangeas, V. Nasser, and H. Avet-loiseau, Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease, Blood, vol.101, issue.>12, pp.4998-5006, 2003.
DOI : 10.1182/blood-2002-11-3385

D. Vos, J. Hose, D. Reme, and T. , Microarray-based understanding of normal and malignant plasma cells, Immunological Reviews, vol.61, issue.1, pp.86-104, 2006.
DOI : 10.1074/jbc.M409807200
URL : https://hal.archives-ouvertes.fr/inserm-00149827

P. Bergsagel, W. Kuehl, and F. Zhan, Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma, Blood, vol.106, issue.1, pp.296-303, 2005.
DOI : 10.1182/blood-2005-01-0034

F. Zhan, Y. Huang, and S. Colla, The molecular classification of multiple myeloma, Blood, vol.108, issue.6, pp.2020-2028, 2006.
DOI : 10.1182/blood-2005-11-013458

J. Shaughnessy, J. Zhan, F. Burington, and B. , A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1, Blood, vol.109, issue.6, pp.2276-84, 2007.
DOI : 10.1182/blood-2006-07-038430

F. Zhan, S. Colla, and X. Wu, CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms, Blood, vol.109, issue.11, pp.4995-5001, 2007.
DOI : 10.1182/blood-2006-07-038703

D. Hose, J. Rossi, and C. Ittrich, Molecular Classification of Multiple Myeloma (MM) Based on Gene Expression Profiling (GEP) and Fluorescence In Situ Hybridisation (FISH) Is an Independent Predictor for Event Free Survival (EFS) Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma, Blood (ASH Annual Meeting Abstracts) Cancer Cell, vol.10612, pp.131-175, 2005.

C. Annunziata, R. Davis, and Y. Demchenko, Frequent Engagement of the Classical and Alternative NF-??B Pathways by Diverse Genetic Abnormalities in Multiple Myeloma, Cancer Cell, vol.12, issue.2, pp.115-145, 2007.
DOI : 10.1016/j.ccr.2007.07.004

M. Jourdan, J. Moreaux, and J. Vos, B pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth, British Journal of Haematology, vol.83, issue.2, pp.160-168, 2007.
DOI : 10.1111/j.1365-2141.2007.06629.x
URL : https://hal.archives-ouvertes.fr/inserm-00160647

J. Rossi, J. Moreaux, and M. Rose, A Phase I/II Study of Atacicept (TACI-Ig) To Neutralize APRIL and BLyS in Patients with Refractory or Relapsed Multiple Myeloma (MM) or Active Previously Treated Waldenstrom's Macroglobulinemia (WM), Blood (ASH Annual Meeting Abstracts), vol.108, p.3578, 2006.

J. Moreaux, F. Cremer, and T. Reme, The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature, Blood, vol.106, issue.3, pp.1021-1051, 2005.
DOI : 10.1182/blood-2004-11-4512
URL : https://hal.archives-ouvertes.fr/inserm-00129406

D. Vos, J. Couderc, G. Tarte, and K. , Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays, Blood, vol.98, issue.3, pp.771-80, 2001.
DOI : 10.1182/blood.V98.3.771

K. Tarte, D. Vos, J. Thykjaer, and T. , Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts, Blood, vol.100, pp.1113-1135, 2002.

D. Vos, J. Thykjaer, T. Tarte, and K. , Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays, Oncogene, vol.99, issue.44, pp.6848-57, 2002.
DOI : 10.1038/sj.onc.1205868

F. Zhan, J. Hardin, and B. Kordsmeier, Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells, Blood, vol.99, issue.5, pp.1745-57, 2002.
DOI : 10.1182/blood.V99.5.1745

N. Munshi, T. Hideshima, and D. Carrasco, Identification of genes modulated in multiple myeloma using genetically identical twin samples, Blood, vol.103, issue.5, pp.1799-806, 2004.
DOI : 10.1182/blood-2003-02-0402

A. Barclay, G. Wright, G. Brooke, and . Brown, CD200 and membrane protein interactions in the control of myeloid cells, Trends in Immunology, vol.23, issue.6, pp.285-90, 2002.
DOI : 10.1016/S1471-4906(02)02223-8

J. Moreaux, D. Hose, and T. Reme, CD200 is a new prognostic factor in multiple myeloma, Blood, vol.108, issue.13, pp.4194-4201, 2006.
DOI : 10.1182/blood-2006-06-029355
URL : https://hal.archives-ouvertes.fr/inserm-00130595

A. Kretz-rommel, F. Qin, and N. Dakappagari, CD200 Expression on Tumor Cells Suppresses Antitumor Immunity: New Approaches to Cancer Immunotherapy, The Journal of Immunology, vol.178, issue.9, pp.5595-605, 2007.
DOI : 10.4049/jimmunol.178.9.5595

F. Davies, A. Dring, and C. Li, Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis, Blood, vol.102, issue.13, pp.4504-4515, 2003.
DOI : 10.1182/blood-2003-01-0016

J. Shaughnessy, J. Zhan, F. Barlogie, B. , and S. , Gene expression profiling and multiple myeloma, Best Practice & Research Clinical Haematology, vol.18, issue.4, pp.537-52, 2005.
DOI : 10.1016/j.beha.2005.02.003

F. Zhan, B. Barlogie, and V. Arzoumanian, Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis, Blood, vol.109, issue.4, 2006.
DOI : 10.1182/blood-2006-07-037077

N. Hynes and H. Lane, ERBB receptors and cancer: the complexity of targeted inhibitors, Nature Reviews Cancer, vol.7, issue.5, pp.341-54, 2005.
DOI : 10.1021/jm00130a020

K. Mahtouk, D. Hose, and T. Reme, Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells, Oncogene, vol.83, issue.21, pp.3512-3536, 2005.
DOI : 10.1038/sj.onc.1208536
URL : https://hal.archives-ouvertes.fr/inserm-00130206

K. Mahtouk, J. M. , D. Vos, and J. , An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis, Blood, vol.103, issue.5, pp.1829-1866, 2004.
DOI : 10.1182/blood-2003-05-1510
URL : https://hal.archives-ouvertes.fr/inserm-00130207

F. Mackay and A. , The TNF family members BAFF and APRIL: the growing complexity, Cytokine & Growth Factor Reviews, vol.14, issue.3-4, pp.311-335, 2003.
DOI : 10.1016/S1359-6101(03)00023-6

A. Novak, J. Darce, and B. Arendt, Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival, Blood, vol.103, issue.2, pp.689-94, 2004.
DOI : 10.1182/blood-2003-06-2043

P. Croonquist, M. Linden, F. Zhao, V. Ness, and B. , Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells, Blood, vol.102, issue.7, pp.2581-92, 2003.
DOI : 10.1182/blood-2003-04-1227

K. Brocke-heidrich, A. Kretzschmar, and G. Pfeifer, Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation, Blood, vol.103, issue.1, pp.242-51, 2004.
DOI : 10.1182/blood-2003-04-1048

M. Chatterjee, T. Stuhmer, and P. Herrmann, Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells, Blood, vol.104, issue.12, pp.3712-3733, 2004.
DOI : 10.1182/blood-2004-04-1670

M. Chatterjee, S. Jain, and T. Stuhmer, STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90?? and ?? in multiple myeloma cells, which critically contribute to tumor-cell survival, Blood, vol.109, issue.2, pp.720-728, 2007.
DOI : 10.1182/blood-2006-05-024372

D. Chauhan, D. Auclair, and E. Robinson, Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays, Oncogene, vol.21, issue.9, pp.1346-58, 2002.
DOI : 10.1038/sj.onc.1205205

D. Chauhan, G. Li, and D. Auclair, Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays, Blood, vol.101, issue.9, pp.3606-3620, 2003.
DOI : 10.1182/blood-2002-10-3146

C. Mitsiades, N. Mitsiades, and C. Mcmullan, Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications, Proceedings of the National Academy of Sciences, vol.101, issue.2, pp.540-545, 2004.
DOI : 10.1073/pnas.2536759100

N. Mitsiades, C. Mitsiades, and V. Poulaki, Molecular sequelae of proteasome inhibition in human multiple myeloma cells, Proceedings of the National Academy of Sciences, vol.99, issue.22, pp.14374-14383, 2002.
DOI : 10.1073/pnas.202445099

G. Mulligan, C. Mitsiades, and B. Bryant, Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib, Blood, vol.109, issue.8, 2006.
DOI : 10.1182/blood-2006-09-044974

J. Corre, K. Mahtouk, and M. Attal, Bone marrow mesenchymal stem cells are abnormal in multiple myeloma, Leukemia, vol.63, pp.1079-88, 2007.
DOI : 10.1038/sj.leu.2404621
URL : https://hal.archives-ouvertes.fr/inserm-00270565

K. Mahtouk, D. Hose, and P. Raynaud, Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma, Blood, vol.109, issue.11, pp.4914-4937, 2007.
DOI : 10.1182/blood-2006-08-043232
URL : https://hal.archives-ouvertes.fr/inserm-00136105

Y. Yang, V. Macleod, and H. Miao, Heparanase Enhances Syndecan-1 Shedding: A NOVEL MECHANISM FOR STIMULATION OF TUMOR GROWTH AND METASTASIS, Journal of Biological Chemistry, vol.282, issue.18, pp.13326-13359, 2007.
DOI : 10.1074/jbc.M611259200

R. Sanderson, Y. Yang, L. Suva, and K. , Heparan sulfate proteoglycans and heparanase???partners in osteolytic tumor growth and metastasis, Matrix Biology, vol.23, issue.6, pp.341-52, 2004.
DOI : 10.1016/j.matbio.2004.08.004

S. Yaccoby, M. Wezeman, and A. Henderson, Cancer and the Microenvironment: Myeloma-Osteoclast Interactions as a Model, Cancer Research, vol.64, issue.6, pp.2016-2039, 2004.
DOI : 10.1158/0008-5472.CAN-03-1131

E. Tian, F. Zhan, and R. Walker, The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma, New England Journal of Medicine, vol.349, issue.26, pp.2483-94, 2003.
DOI : 10.1056/NEJMoa030847

S. Assou, T. Lecarrour, and S. Tondeur, A Meta-Analysis of Human Embryonic Stem Cells Transcriptome Integrated into a Web-Based Expression Atlas, Stem Cells, vol.22, issue.4, 2007.
DOI : 10.1634/stemcells.2006-0352
URL : https://hal.archives-ouvertes.fr/inserm-00128925